Novel Targets You Haven’t Considered
Not literature repeats. Not obvious biology. Mechanistically aligned targets surfaced through multi-omic phenotype matching.
Pipeline Intelligence
See What Plex Can Do for Your Drug Pipeline
Your next breakthrough program is already hiding in data. Plex finds it. Get a personalized AI-generated report showing exactly where your pipeline has hidden upside, overlooked targets, and mechanistic blind spots.
The Challenge
You’re Sitting on Opportunity
Most drug programs stall because:
- Targets lack true mechanistic validation
- Safety risks show up too late
- Differentiation vs. standard of care is unclear
- Biomarkers are an afterthought
- Teams rely on fragmented datasets and manual synthesis
Plex eliminates that uncertainty.
What You Get
What You’ll Discover
Early Safety Signal Detection
We flag transcriptomic overlap with known toxicity phenotypes before you burn millions in preclinical work.
True Mechanism Differentiation
See how your opportunity differs — at the molecular level — from current therapies.
Translational Biomarker Strategy
Get biomarker hypotheses that support faster Phase I/II signal detection.
Strategic Whitespace in Your Therapeutic Area
Where incumbents cluster. Where innovation is still open. Where you can win.
Our Approach
Why Plex Is Different
Most ‘AI for drug discovery’ tools retrieve papers. Plex performs mechanistic signal alignment across thousands of functional genomics datasets:
Standard Approach
“What does literature say?”
Plex Approach
“What molecular perturbations recreate the phenotype you want — without recreating the toxicity you don’t?”
That’s a different level of intelligence.
Report Contents
Inside Your Free Report
- 1Ranked novel program hypotheses
- 2Mechanism-of-action summary
- 3Supporting multi-source evidence
- 4Predicted safety liabilities
- 5Tissue compatibility analysis
- 6Competitive landscape scan
- 7Biomarker opportunities
Who This Is For
This is not for casual curiosity.
This is for:
- Heads of Discovery
- Translational Science Leaders
- Computational Biology Teams
- Portfolio Strategy Executives
- Biotech CEOs building differentiated pipelines
If you’re responsible for capital allocation in R&D — you should see this.
Get Started